Therapeutic DNP derivatives and methods using same
The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
1. A method of ameliorating a disease or disorder in a subject in need thereof, wherein the disease or disorder is at least one selected from the group consisting of hypertriglyceridemia, fatty liver, and insulin resistance, the method comprising:
administering to the subject a therapeutically effective amount of a nitrophenyl derivative selected from the group consisting of 2,4-dinitrophenyl vinyl ether, 2,4-dinitrophenyl methyl ether-d 6 , and solvates thereof.
2. The method of claim 1 , wherein the method further comprises administering to the subject at least one additional therapeutic agent.
3. The method of claim 2 , wherein the nitrophenyl derivative and the at least one additional therapeutic agent are co-administered to the subject.
4. The method of claim 3 , wherein the nitrophenyl derivative and the at least one additional therapeutic agent are co-formulated.
5. The method of claim 1 , wherein the subject is a mammal.
6. The method of claim 5 , wherein the mammal is human.
7. The method of claim 1 , wherein the administering is by an administration route selected from the group consisting of oral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical.
8. The method of claim 7 , wherein the administering is oral and wherein the nitrophenyl derivative is formulated as a tablets, dragee, liquid, drop, capsule, caplet, or gelcap.
9. A method of increasing energy expenditure in a subject afflicted with at least one disease or disorder selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic steatosis, type 2 diabetes (T2D), acquired lipodystrophy, lipodystrophy (inherited), partial lipodystrophy, hypertriglyceridemia, obesity, metabolic syndrome, Rett's syndrome, Friedreich's ataxia, and insulin resistance, the method comprising:
administering to the subject a therapeutically effective amount of a nitrophenyl derivative selected from the group consisting of 2,4-dinitrophenyl vinyl ether, 2,4-dinitrophenyl methyl ether-d 6 , and solvates thereof,
whereby energy expenditure in the subject is increased.
10. The method of claim 9 , wherein the therapeutically effective amount of the nitrophenyl derivative is about 25 μmoles/kg.
11. The method of claim 9 , wherein the subject is a mammal.
12. The method of claim 11 , wherein the mammal is human.
13. The method of claim 9 , wherein the administering is by an administration route selected from the group consisting of oral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical.
14. The method of claim 13 , wherein the administering is oral and wherein the nitrophenyl derivative is formulated as a tablets, dragee, liquid, drop, capsule, caplet, or gelcap.
15. A method of uncoupling mitochondria in the liver of a subject, the method comprising:
administering to the subject a therapeutically effective amount of a nitrophenyl derivative selected from the group consisting of 2,4-dinitrophenyl methyl ether, 2,4-dinitrophenyl vinyl ether, 2,4-dinitrophenyl methyl ether-d 6 , and solvates thereof,
wherein mitochondria in the liver of the subject are selectively uncoupled.
16. The method of claim 15 , wherein the subject is a mammal.
17. The method of claim 15 , wherein the mammal is human.
18. The method of claim 15 , wherein the administering is by an administration route selected from the group consisting of oral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical.
19. The method of claim 18 , wherein the administering is oral and wherein the nitrophenyl derivative is formulated as a tablets, dragee, liquid, drop, capsule, caplet, or gelcap.
20. The method of claim 15 , wherein the nitrophenyl derivative is administered in an amount of about 0.1 mg to about 1000 mg to the subject.